Paper39543737
Near-infrared fluorescent molecular probes with cetuximab in the in vivo fluorescence imaging for epithelial ovarian cancer.
Zhang C and 7 others. J Ovarian Res, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Near-infrared fluorescent molecular probes with cetuximab in the in vivo fluorescence imaging for epithelial ovarian cancer. Papers, record 39543737. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39543737
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Near-infrared fluorescent molecular probes with cetuximab in the in vivo fluorescence imaging for epithelial ovarian cancer.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cetuximab | Major topic |
| Optical Imaging | Major topic |
| Carcinoma, Ovarian Epithelial | Major topic |
| Fluorescent Dyes | Major topic |
| Ovarian Neoplasms | Major topic |
| ErbB Receptors | Major topic |
| Female | |
| Humans | |
| Animals | |
| Cell Line, Tumor | |
| Mice | |
| Xenograft Model Antitumor Assays | |
| Mice, Nude | |
| Disease Models, Animal |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No.2016YFA0201400 | National Key Research and Development Program of China | PubMed | ||
| No. 2022YFC2704204 | National Key Research and Development Program of China | PubMed | ||
| No. 7222202 | Natural Science Foundation of Beijing Municipality | PubMed | ||
| No. 7222204 | Natural Science Foundation of Beijing Municipality | PubMed |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29721094 | Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. | Theranostics | 2018 | https://conductscience.org/library/papers/29721094 | PubMed |
| 2 | 23591395 | Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. | Biomaterials | 2013 | https://conductscience.org/library/papers/23591395 | PubMed |
| 3 | 32660222 | EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells. | Iran Biomed J | 2020 | https://conductscience.org/library/papers/32660222 | PubMed |
| 4 | 36070540 | A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36070540 | PubMed |
| 5 | 26110901 | The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/26110901 | PubMed |
| 6 | 25904751 | Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25904751 | PubMed |
| 7 | 21909139 | Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. | Oncogene | 2012 | https://conductscience.org/library/papers/21909139 | PubMed |
| 8 | 31564810 | Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging. | Chin J Cancer Res | 2019 | https://conductscience.org/library/papers/31564810 | PubMed |
| 9 | 11562388 | Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. | J Natl Cancer Inst | 2001 | https://conductscience.org/library/papers/11562388 | PubMed |
| 10 | 23144806 | Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. | PLoS One | 2012 | https://conductscience.org/library/papers/23144806 | PubMed |
| 11 | 26595119 | A small-molecule dye for NIR-II imaging. | Nat Mater | 2016 | https://conductscience.org/library/papers/26595119 | PubMed |
| 12 | 35420035 | NIR-II Navigation with an EGFR-Targeted Probe Improves Imaging Resolution and Sensitivity of Detecting Micrometastases in Esophageal Squamous Cell Carcinoma Xenograft Models. | Mol Pharm | 2022 | https://conductscience.org/library/papers/35420035 | PubMed |
| 13 | 35485744 | Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma. | Eur J Cardiothorac Surg | 2022 | https://conductscience.org/library/papers/35485744 | PubMed |
| 14 | 35517713 | Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW. | Mol Imaging | 2022 | https://conductscience.org/library/papers/35517713 | PubMed |
| 15 | 31362825 | A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. | Gynecol Oncol | 2019 | https://conductscience.org/library/papers/31362825 | PubMed |
| 16 | 36207638 | New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue. | Eur J Nucl Med Mol Imaging | 2023 | https://conductscience.org/library/papers/36207638 | PubMed |
| 17 | 37041632 | Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37041632 | PubMed |
| 18 | 18222534 | Folate receptor alpha as a tumor target in epithelial ovarian cancer. | Gynecol Oncol | 2008 | https://conductscience.org/library/papers/18222534 | PubMed |
| 19 | 33765422 | Real-time fluorescence imaging in intraoperative decision making for cancer surgery. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33765422 | PubMed |
| 20 | 30664215 | Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway. | Mol Med Rep | 2019 | https://conductscience.org/library/papers/30664215 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42198268 | Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42198268 | PubMed |
| 41036172 | In vivo 3D imaging of ovarian cancer outgrowth in transgenic mouse model with optical coherence tomography. | J Biomed Opt | 2025 | https://conductscience.org/library/papers/41036172 | PubMed |
| 40661211 | Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics. | RSC Adv | 2025 | https://conductscience.org/library/papers/40661211 | PubMed |
| 40293497 | Exploring the mechanisms of cinobufotalin in ovarian cancer treatment: An integrated approach combining network pharmacology, molecular docking and RNA Sequencing. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40293497 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39543737
GET https://conductscience.org/api/papers/v1/39543737/references?page=2